AGRX - Agile Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Princeton,
United States
Type: Equity
AGRX price evolution
AGRX
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.56 | $2.87 | $2.79 | $4.43 |
| Short term investments | ||||
| Net receivables | $3.39 | $3.52 | $4.46 | $3.12 |
| Inventory | $2.74 | $2.41 | $2.54 | $2.21 |
| Total current assets | $9.53 | $10.06 | $11.65 | $10.91 |
| Long term investments | ||||
| Property, plant & equipment | $0.49 | $0.59 | $0.68 | $0.78 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.72 | $0.82 | $0.92 | $2.79 |
| Total investments | ||||
| Total assets | $10.26 | $10.89 | $12.57 | $13.7 |
| Current liabilities | ||||
| Accounts payable | $9.57 | $6.88 | $6.16 | $10.36 |
| Deferred revenue | ||||
| Short long term debt | $1.71 | $1.97 | $2.06 | $1.51 |
| Total current liabilities | $20.78 | $17.54 | $15.31 | $18.51 |
| Long term debt | $0.1 | $0.2 | $0.29 | $0.38 |
| Total noncurrent liabilities | $5.8 | $5.76 | $9.38 | $4.63 |
| Total debt | $1.81 | $2.16 | $2.35 | $1.89 |
| Total liabilities | $26.57 | $23.3 | $24.69 | $23.13 |
| Shareholders' equity | ||||
| Retained earnings | -$423.17 | -$418.7 | -$417.9 | -$414.09 |
| Other shareholder equity | -$0 | -$0 | ||
| Total shareholder equity | -$16.32 | -$12.41 | -$12.12 | -$9.43 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.56 | $5.25 | $19.14 | $14.46 |
| Short term investments | $40.01 | |||
| Net receivables | $3.39 | $3.38 | $1.53 | $0.86 |
| Inventory | $2.74 | $1.33 | $0.97 | |
| Total current assets | $9.53 | $11.36 | $23.93 | $56.78 |
| Long term investments | ||||
| Property, plant & equipment | $0.49 | $0.87 | $13.4 | $14.38 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $0.72 | $2.88 | $15.41 | $16.28 |
| Total investments | $40.01 | |||
| Total assets | $10.26 | $14.24 | $39.33 | $73.06 |
| Current liabilities | ||||
| Accounts payable | $9.57 | $7.73 | $8.71 | $3.87 |
| Deferred revenue | ||||
| Short long term debt | $1.71 | $1.43 | $16.83 | |
| Total current liabilities | $20.78 | $13.39 | $29.28 | $7.35 |
| Long term debt | $0.1 | $0.47 | $0.78 | $16.38 |
| Total noncurrent liabilities | $5.8 | $6.4 | $0.78 | $16.38 |
| Total debt | $1.81 | $1.89 | $17.62 | $16.38 |
| Total liabilities | $26.57 | $19.79 | $30.06 | $23.73 |
| Shareholders' equity | ||||
| Retained earnings | -$423.17 | -$408.7 | -$387.12 | -$312.22 |
| Other shareholder equity | $0 | |||
| Total shareholder equity | -$16.32 | -$5.54 | $9.27 | $49.33 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.61 | $6.66 | $5.5 | $3.81 |
| Cost of revenue | $2.19 | $2.48 | $2.31 | $2 |
| Gross Profit | $1.42 | $4.18 | $3.2 | $1.81 |
| Operating activities | ||||
| Research & development | $0.05 | $0.7 | $0.7 | $0.76 |
| Selling, general & administrative | $5.42 | $7.48 | $7.62 | $7.75 |
| Total operating expenses | $5.47 | $8.19 | $8.32 | $8.52 |
| Operating income | -$4.05 | -$4 | -$5.13 | -$6.71 |
| Income from continuing operations | ||||
| EBIT | -$4.17 | -$0.46 | -$3.44 | -$4.99 |
| Income tax expense | ||||
| Interest expense | $0.3 | $0.34 | $0.37 | $0.4 |
| Net income | ||||
| Net income | -$4.47 | -$0.8 | -$3.81 | -$5.39 |
| Income (for common shares) | -$4.47 | -$0.8 | -$3.81 | -$5.39 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $19.59 | $10.88 | $4.1 | $0.75 |
| Cost of revenue | $8.98 | $6.84 | $10.72 | $0.28 |
| Gross Profit | $10.62 | $4.05 | -$6.62 | $0.47 |
| Operating activities | ||||
| Research & development | $2.23 | $3.25 | $6.25 | $13.5 |
| Selling, general & administrative | $28.27 | $42.23 | $58.14 | $36.02 |
| Total operating expenses | $30.5 | $56.6 | $64.39 | $49.52 |
| Operating income | -$19.88 | -$52.56 | -$71 | -$49.05 |
| Income from continuing operations | ||||
| EBIT | -$13.05 | -$26.96 | -$70.98 | -$48.74 |
| Income tax expense | -$4.67 | |||
| Interest expense | $1.42 | $3.13 | $3.91 | $3.11 |
| Net income | ||||
| Net income | -$14.46 | -$25.41 | -$74.89 | -$51.85 |
| Income (for common shares) | -$14.46 | -$25.41 | -$74.89 | -$51.85 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$4.47 | -$0.8 | -$3.81 | -$5.39 |
| Operating activities | ||||
| Depreciation | $0.1 | $0.1 | $0.1 | $0.09 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.56 | $0.44 | $0.48 | $0.5 |
| Total cash flows from operations | $0.17 | $0.36 | -$8.52 | -$1.59 |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0 | $0.07 | $7.16 | $1 |
| Net borrowings | -$0.49 | -$0.35 | -$0.29 | -$0.23 |
| Total cash flows from financing | -$0.49 | -$0.28 | $6.88 | $0.78 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.32 | $0.09 | -$1.64 | -$0.82 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$14.46 | -$25.41 | -$74.89 | -$51.85 |
| Operating activities | ||||
| Depreciation | $0.39 | $1.53 | $2.22 | $0.28 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.98 | $2.49 | $3.34 | $2.82 |
| Total cash flows from operations | -$9.58 | -$35.95 | -$65.2 | -$47.31 |
| Investing activities | ||||
| Capital expenditures | -$0.13 | -$0.27 | -$0.35 | |
| Investments | $39.73 | -$40.34 | ||
| Total cash flows from investing | -$0.13 | $39.46 | -$40.69 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $8.23 | $35.43 | $30.42 | $49.04 |
| Net borrowings | -$1.35 | -$17.38 | $20 | |
| Total cash flows from financing | $6.89 | $22.18 | $30.42 | $67.98 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$2.69 | -$13.9 | $4.68 | -$20.02 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $19.59M |
|---|---|
| EBITDA | -$12.66M |
| EBIT | -$13.05M |
| Net Income | -$14.47M |
| Revenue Q/Q | -9.56% |
| Revenue Y/Y | 79.99% |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | -122.06% |
| ROE | 115.09% |
| Debt/Equity | -1.63 |
|---|---|
| Net debt/EBITDA | -1.90 |
| Current ratio | 0.46 |
| Quick ratio | 0.33 |